Click to open contact form.
Your Global Partners in the Business of Innovation

Congratulations to our client Humanigen and Dr. Cameron Durrant, CEO, on completing its equity financing round of $71.8M

Client Update / Jun 07, 2020

Humanigen, Inc., (OTCQB:HGEN), a clinical stage biopharmaceutical company focused on preventing and treating cytokine storm with lenzilumab, the company’s proprietary Humaneered® anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody, announced today the pricing of a private placement of approximately $72 million of common stock.  J.P. Morgan Securities LLC is acting as the placement agent for the financing, which comprises a group of healthcare investors including Venrock Healthcare Capital Partners, Surveyor Capital (a Citadel company), HealthCor, Valiant Capital Partners, First Light Asset Management and Ghost Tree Capital.

CLICK HERE to see full article

Mark Cohen, Senior Partner and Chair of the Life Sciences Practice Group, and Elizabeth Wieckowski represent Humanigen in its intellectual property matters.

INNOVATION HIGHLIGHTS